The incidence of obesity (especially childhood obesity) and its associated health-related problems have reached epidemic proportions in the United States. Recent investigations suggest that the causes of obesity involve a complex interplay of genetic, environmental, psychobehavioral, endocrine, metabolic, cultural, and socioeconomic factors. Several genes and their protein products, such as leptin, may be particularly important in appetite and metabolic control, although the genetics of human obesity appear to involve multiple genes and metabolic pathways that require further elucidation. Severe obesity is frequently associated with significant comorbid medical conditions, including coronary artery disease, hypertension, type II diabetes mellitus, gallstones, nonalcoholic steatohepatitis, pulmonary hypertension, and sleep apnea. Long-term reduction of significant excess weight in these patients may improve or resolve many of these obesity-related health problems, although convincing evidence of long-term benefit is lacking. Available treatments of obesity range from diet, exercise, behavioral modification, and pharmacotherapy to surgery, with varying risks and efficacy. Nonsurgical modalities, although less invasive, achieve only relatively short-term and limited weight loss in most patients. Currently, surgical therapy is the most effective modality in terms of extent and duration of weight reduction in selected patients with acceptable operative risks. The most widely performed surgical procedure, Roux-en-Y gastric bypass, achieves permanent (followed up for more than 14 years) and significant weight loss (more than 50% of excess body weight) in more than 90% of patients.
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T he notion that obesity is the result of a lack of willpower on the part of affected individuals is simplistic, unscientific, and counterproductive in combating this disease. It is increasingly clear that the regulation of body weight is dependent on multiple biologic factors modified by various environmental and psychosocial factors. The food intake of an average adult matches energy expenditure within 0.17% per decade, 1 indicating the presence of a biologic regulatory system with remarkable precision in energy metabolism. Although the influence of genetic factors on the expression of obesity has been demonstrated repeatedly, 2-4 the recent explosion in the prevalence of obesity is most likely caused by environmental and behavioral changes. Nevertheless, recent advances in the genetics of obesity and in energy metabolism should yield new insights into fundamental physiologic regulatory processes and may lead to more effective and specific therapies.
The degree of obesity is most conveniently quantified by the body mass index (BMI) because of its ease of calculation and relatively accurate correlation with body fat content. BMI represents a ratio of weight and body surface area, expressed as weight (kilograms) divided by the square of height (square meters). Conventional categories of relative body weight corresponding to BMI are shown in Table 1 . 5 Using these categories, more than half of all adults 6 and approximately a quarter of all children are overweight (BMI Ͼ 25) or obese (BMI Ͼ 30), 7 and 18% of all Americans are obese (BMI Ͼ 30). 8, 9 Approximately 280,000 annual deaths are estimated to be attributable to obesity in the United States. 10 Four of 5 obese people have at least one debilitating illness associated with the underlying obesity. In developed countries, obesity is more common among those of lower socioeconomic status. The prevalence of obesity is higher in certain ethnic groups such as African Americans and Mexican Americans. U.S. public health officials indicate that obesity currently is not effectively addressed (Healthy People 2010). For example, in a recent community-based study over a 3-year period, more than half (53.7%) of the subjects gained weight, whereas only a quarter (24.5%) were able to avoid a weight gain, and successful weight loss and maintenance were seen in less than 5% (4.6%). 11 The urgency of the current weight problem is also reflected by the most recent top 10 leading health indicator list, in which the top 2 are physical activity and obesity, which rank above tobacco use. Many epidemiology studies have documented a close relationship between increasing adiposity and death rates. [12] [13] [14] [15] Figure 1 represents one of many BMI versus mortality curves, illustrating an exponential increase in mortality risk with obesity. A recent prospective study again confirmed that obesity is closely associated with an increased risk of death from all causes, including cardiovascular disease and cancer. 16 The mechanisms regulating overall energy balance and weight are incompletely understood. In 1994, the ob gene and its protein product leptin were identified by positional cloning from ob Ϫ/Ϫ mice. 17 Leptin, a 167-amino acid protein produced by adipocytes, appears to be an afferent signal for satiety in mice. 18 In ob Ϫ/Ϫ mice, the lack of functional leptin leads to hyperphagia and obesity, and its replacement reverses the weight gain. Although both leptin deficiency 19 and a leptin receptor defect 20 have been identified in humans, only a handful of cases can be attributed to these; almost all obese human patients instead display leptin resistance. 18, 21 The role of leptin in humans is not as straightforward as in mice, although it appears to be an important metabolic signaling molecule that regulates energy expenditure as well as food intake. 22 Leptin receptors are richly expressed in the arcuate nucleus of the hypothalamus, which expresses several key molecules regulating food intake ( Figure 2 ). These include neuropeptide Y (NPY) and agouti-related protein, which increase food intake, as well as pro-opiomelanocortin, a precursor of ␣-melanocyte-stimulating hormone, and cocaine-and amphetamine-regulated transcript, which decrease food intake ( Figure 2 ). [23] [24] [25] Mutations in pro-opiomelanocortin and a melanocyte-stimulating hormone receptor have been demonstrated to be associated with obesity and leptin resistance. 26, 27 Adaptive thermogenesis (regulated production of heat) is an important element of energy expenditure. Some of the key agents in the regulation of thermogenesis such as uncoupling proteins 28, 29 and peroxisome proliferator-activated receptor ␥ coactivator 1 30 appear to be modulated by leptin. 31, 32 Human leptin trials for the treatment of obesity are currently in progress. Because most obese patients have leptin resistance, the potential of high-dose exogenous leptin for antiobesity therapy is uncertain, although the analogous strategy of insulin treatment for insulin-resistant type II diabetes mellitus has been successful. Decreased leptin levels may, at least in part, be responsible for high failure rates in diet therapy of obesity. The notion of combining leptin replacement with a diet is an attractive possible new approach to the medical management of obesity. Activation of thermogenesis and lipolysis by stimulation of the ␤ 3 -adrenergic receptor is another avenue for new drug development. 
What Is Morbid About Morbid Obesity?
Severe obesity is associated with the development of a variety of medical conditions, thus the term morbid obesity. Premature mortality has been repeatedly observed in severely obese patients. 16, 33, 34 Some of the contributing conditions include coronary artery disease, hypertension, type II diabetes mellitus, sleep apnea syndrome, obesity hypoventilation syndrome, and necrotizing panniculitis. Morbid obesity is also associated with numerous other disabling conditions such as chronic venous stasis disease, osteoarthritis, urinary incontinence, gastroesophageal reflux disease, fatty liver, cholelithiasis, idiopathic intracranial hypertension (pseudotumor cerebri), sex hormone dysfunction, and clinical depression. Many of these comorbidities are closely related to the increased intra-abdominal pressure and sagittal abdominal wall diameter. 35 Increased risk is observed in obese patients for the development of various cancers, including breast, colon, uterine, and prostate cancer. Table 2 lists various obesity comorbidities encountered in the clinical setting.
Does Weight Loss Reduce the Morbidity of Obesity?
The purpose of treatment for obesity is to restore normal metabolic and organ function. It should be remembered that the goal of any antiobesity therapy is not to reduce weight per se, but to reduce the disability and morbidity, and thus to increase the quality of life. The rationale for treatment of obesity is not only the increased mortality attributable to obesity, but also the numerous lines of evidence suggesting that weight loss reduces risk factors for comorbid disease. 5 A modest to moderate loss of excess weight (the difference between actual weight and the ideal body weight for a given height) achieved by life-style changes has been shown to reduce blood pressure in overweight hypertensive 36, 37 and nonhypertensive patients, 38 to improve serum lipid profile (reduced triglyceride and total and low-density lipoprotein cholesterol levels, along with increased highdensity lipoprotein cholesterol levels), 39, 40 and to improve glucose tolerance and fasting glucose levels in normoglycemic and diabetic patients. [41] [42] [43] Diet, exercise, and standard behavior modification have been the traditional methods, but these do not always work by themselves. Pharmacologic treatments have yielded mixed results over the years, with some patients responding well but others not at all. Recently, a new generation of drugs promises hope for treatment of those with clinically significant obesity, but to date these therapies have not been shown to be effective for cases of severe obesity.
Surgical treatments for obesity in general achieve more profound and long-lasting weight loss and improve or resolve most comorbidities of severe obesity. In addition to the improvements in hypertension, 44, 45 serum lipid levels, 46 and diabetes mellitus, 47, 48 weight reduction by surgery improves respiratory insufficiency caused by sleep apnea and obesity hypoventilation syndrome, 49, 50 reflux esophagitis, 51, 52 pseudotumor cerebri, 53 and venous stasis ulcers. 35 However, a more recent study by Sjostrom et al. 54 shows differential effects of long-term (8 years) surgical weight loss on diabetes and hypertension. Although surgical weight loss was associated with sig- 
Medical Therapy
Capitalizing on the increased market for obesity therapy, numerous commercial programs have sprung up across the United States and formed a thriving multibillion dollar industry. These nonsurgical programs are classified into 4 basic approaches: diet, exercise, behavior modification, and drugs. Accumulating data reveal the effectiveness of these modalities in inducing modest weight loss in many participants; however, these approaches are usually effective only in the short run, and indefinite continuation of such treatments is usually difficult for patients to sustain. Studies are ongoing, particularly in search of safe and effective drug therapies directed against the molecular defects of obesity.
Diet Therapy
Theoretically, it should be a simple matter to achieve weight loss by dieting, producing an energy deficit in which intake is less than energy expenditure. As so many can attest by their own personal experience, this approach is far more difficult to put into action in an environment where delicious, high-calorie foods are abundant and easily obtained. This inherent difficulty is well illustrated by the typical results of many diet programs, in which early weight loss is achieved by most patients, but the weight loss is not maintained over the long term.
A comprehensive and critical evaluation of multiple dietary clinical trials was carried out by an expert panel convened by the National Institutes of Health (NIH) in 1998 in an effort to establish evidence-based guidelines for the treatment of obesity. 5 Despite confounding factors from various studies, several key conclusions could be agreed upon. First, dietary caloric reduction is indeed associated with weight loss. Low-calorie diets (LCDs) consisting of 1000 -1200 kcal/day can reduce total body weight by an average of 8% over 3-12 months. Very low-calorie diets (VLCDs) with 400 -500 kcal/day produce greater initial weight loss than LCDs, but the long-term (Ͼ1 year) weight loss is not different from that of LCDs. Second, a change in diet composition by fat reduction is associated with weight loss. Lower-fat diets (LFDs), deriving 20%-30% of calories from fat, help promote weight loss by producing a reduced caloric intake. LFDs coupled with total caloric reduction produce greater weight loss than LFDs alone. LFDs produce weight loss primarily by decreasing caloric intake. Based on these findings, the panel recommends (1) LCDs for weight loss in overweight and obese patients and (2) reduction of fat as part of an LCD to reduce calories. Because there is little evidence that LFDs per se cause weight loss independent of caloric reduction, reduction in total caloric intake is the most important factor in weight loss.
Carbohydrate restriction has been the basis for several popular diets in the past, and has recently been resurrected as the "Atkins diet" and the "zone diet." 55, 56 The basic premise of low-carbohydrate diets is that excessive carbohydrates induce increased levels of insulin that promote transport and storage of fat. Low-carbohydrate diets, consisting inevitably of high levels of protein and fat, promptly induce depletion of liver glycogen storage and systemic ketosis resulting from oxidation of fat. However, short-term weight loss on such diets seems to be caused in large part by the loss of water and electrolytes. 57 This is particularly true during the initial diet phase, in which heavily hydrated glycogen is catabolized to meet energy requirements and maintain blood glucose. Low-carbohydrate, high-protein diets seem particularly effective in suppressing hunger, possibly because of branched-chain amino acid content. 58 Thus, the weight loss may not necessarily be attributable solely to the composition of the diet, but also to reduced total caloric intake. Additionally, a more recent study showed that weight loss is not different between low-and highcarbohydrate diets, 59 indicating that total energy intake, not nutrient composition, determines weight loss. Because long-term studies are not yet available, the longterm safety and efficacy of low-carbohydrate, high-protein/fat diets remain to be established.
Exercise
In our modern, technology-driven age, an everincreasing number of labor-saving conveniences and gadgets contribute to the reduction in average daily energy expenditure that favors the development of obesity. 60 Although physical activity and exercise are key factors in successful weight reduction programs, the contribution of exercise to weight loss is modest at best. For example, approximately 40 miles of walking is required to metabolize 1 kg of fat. The effect of exercise on weight loss is variable, but most studies show only a small reduction (ϳ2 kg), 37, 61, 62 and some show no benefit at all. 63, 64 Furthermore, most studies show that weight loss induced by exercise alone is inferior to that achieved by diet alone. 37, 64, 65 However, exercise is probably independently important to the well-being of overweight and obese individuals because physical activity increases maximal oxygen uptake and thus cardiorespiratory fitness. 37, 63, 64 Moreover, maintenance of weight loss is facilitated by regular exercise. 66 Unfortunately, the unrealistic expectations of weight loss from exercise regimens that are promoted by many commercial enterprises may lead to disappointment and discontinuation of exercise. Development of a consistently achievable exercise program for each overweight patient is essential. Although it is difficult, even the most obese patients may be able to participate in some form of appropriately designed physical activity.
Behavior Therapy
Conditioning probably plays a major role in many behavioral disorders. Like Pavlov's dog, who salivated at the sound of a bell, overweight and obese individuals become conditioned to the repeated association of, for example, pizza and beer with watching sporting events on television. Thus, behavior therapy in obesity is to identify cravings and weaken or disconnect the triggering events that lead to overeating. However, the effectiveness of behavior therapy alone against obesity is modest compared with that reported in other conditions such as depression, anxiety, and bulimia, 67 and it is best combined with other weight loss modalities. When behavior therapy was combined with diet therapy in the form of an LCD or VLCD, maintenance of weight loss at 1 year was better than with diet alone. 68, 69 Similarly, drug therapy with fenfluramine was shown to achieve a better weight loss at 6 months, and better maintenance at 1 year, when combined with behavior therapy. 70 Longterm (1-5 years) follow-up of these patients, however, indicates that most of the subjects in the group regain the lost weight in the absence of continued behavioral intervention. 69, 71 A recent NIH expert panel recommends that behavior therapy be an adjunct treatment for weight loss and weight maintenance. 5 
Pharmacotherapy
Although somewhat effective, drug therapy, like other nonsurgical modalities, achieves only a modest (ϳ10%) weight reduction and requires continued use to maintain this result. In addition, the dangerous adverse effects associated with some drugs, including addiction with amphetamines 72 and valvular heart disease with fenfluramine plus phentermine (fen-phen), 73 have given pharmacotherapy for obesity a bad reputation. However, recent advances in understanding of molecular mechanisms of weight regulation may yet lead to the development of new classes of antiobesity drugs.
Most antiobesity drugs can be classified into 2 major groups by their mechanisms of action: appetite suppression and/or stimulation of thermogenesis and intestinal fat absorption. Fenfluramine and its d isomer dexfenfluramine increase central serotonin release and induce anorexia and weight loss. In one study, dexfenfluramine showed a small but statistically significant advantage in weight loss when 35% of the subjects taking dexfenfluramine (compared with 17% of the placebo group) were able to lose at least 10% of their initial weight. 74 Phentermine is a central adrenergic agonist that leads to appetite suppression and weight loss. 72 Combination therapy with serotonergic (fenfluramine) and the catecholaminergic (phentermine) agents was demonstrated to be effective in weight reduction 75, 76 and became widely popular until an unusual form of valvular heart disease in women taking this combination was reported in 1997 73 and confirmed in other studies. [77] [78] [79] These agents were subsequently withdrawn from the market in 1998. Phentermine alone does not appear to increase valvular heart disease.
Sibutramine, a ␤-phenethylamine, is a selective inhibitor of the reuptake of both serotonin and norepinephrine and is used more widely since the discontinuation of fenfluramine and dexfenfluramine. It induces both decreased food intake and increased thermogenesis. 80 -82 Weight loss induced by sibutramine was shown to be comparable to that induced by dexfenfluramine. 83 In another study, patients taking sibutramine maintained a continued weight loss of 15% over a 1-year period after an initial diet-induced weight loss, and those in the placebo group regained the weight they initially lost. 84 Patients using sibutramine should be monitored for sympathomimetic side effects, including any tachycardia and hypertension.
Orlistat, an inhibitor of pancreatic lipase, decreases fat absorption in the intestine. Orlistat blocks digestion of approximately 30% of ingested dietary triglyceride 85 and has been shown to achieve a weight loss of ϳ10% (compared with ϳ5% in the control group). 86, 87 However, since the induction of fat malabsorption is its basis of action, it is rather common that steatorrhea develops with orlistat if enough fat is ingested during a meal. 88 Caffeine, ephedrine, and the combination of these 2 drugs can reduce food intake and cause thermogenesis by increasing oxygen consumption. 89, 90 The combination of caffeine and ephedrine has been shown to be more effective in inducing weight loss than placebo, caffeine, or ephedrine alone. 91, 92 The weight loss difference between the combination regimen and placebo is relatively small, and neither agent alone produced significantly more weight loss than placebo. 91 Major adverse effects of these agents include tachycardia and palpitations, and the combination of caffeine and ephedrine is not currently approved by the U.S. Food and Drug Administration.
Recent insights into the molecular mechanisms of satiety and thermogenesis present a window of opportunity for novel pharmacotherapies. Potential strategies include targeting the central regulation of food intake using leptin (and leptin analogues), leptin receptor agonists, melanocortin receptor (MC4R) agonists, NPY antagonists, and cocaine-and amphetamine-regulated transcript receptor agonists. Potential drugs that target thermogenesis regulation are also promising, and these include ␤ 3 -adrenergic receptor agonists and agents that activate or increase uncoupling proteins. A major intestinal fatty acid transporter (FATP4) has recently been identified 93 ; specific inhibitors of this transporter could be effective in blocking fat absorption, although the potential for steatorrhea, as with orlistat, must be acknowledged.
Currently, indications for the use of pharmacotherapy for obesity are a BMI of 30 or a BMI of 27 with obesity-related comorbidities. However, no data show that drug treatment of otherwise healthy obese subjects prevents future complications or improves long-term outcome. Moreover, long-term weight loss data are not available. Most patients regain weight once any drug therapy is discontinued, and the success of pharmacotherapy demands life-style changes in diet, exercise, and behavior to increase its effectiveness.
Surgical Therapy
Bariatric procedures for weight reduction share 2 major designs: intestinal malabsorption and gastric restriction. Malabsorptive procedures (Figure 3) involve rearrangement of the small intestine to decrease the functional length or efficiency of the intestinal mucosa for nutrient absorption. Restrictive operations (Figure 4 ) involve creation of a small neogastric pouch and gastric outlet to decrease food intake. Various procedures have evolved from combinations of these 2 principles. Patient selection criteria for surgical treatment of obesity were developed at a 1991 NIH Consensus Development Conference Panel and include patients with BMI Ͼ 40 or BMI Ͼ 35 with obesity-related medical comorbidities. 94 Additional criteria used by most bariatric surgeons as general guidelines are listed in Table 3 . The goals of surgery are to induce and maintain significant loss of excess weight through a safe operation and to improve or resolve many of the comorbid medical problems so that quality of life is enhanced and prolonged. A successful outcome of bariatric surgery depends on several factors. First and foremost is a well-informed and well-educated patient with realistic expectations. It is simply unrealistic to expect total or near-total loss of excess weight with unchanged dietary habits and this expectation can result in patient dissatisfaction postoperatively. A multidisciplinary team capable of providing all aspects of preoperative and postoperative care is thought to be crucial in addressing multiple potential difficulties in the care of these complex patients. Optimally, the team should include dedicated surgeons, internists, psychiatrists, dieticians, nutritionists, and nurses.
Malabsorptive Procedures

Jejunoileal Bypass
The first bariatric operation was jejunoileal bypass, 95 in which an anastomosis of proximal jejunum (14 inches from the ligament of Treitz) to the terminal ileum (4 inches from the ileocecal valve) is created, leaving an extended loop excluded from the food stream ( Figure  3A) . The jejunoileal bypass is exclusively a malabsorptive procedure because the stomach is not modified to limit food intake. Although this operation requires no significant changes in eating habits to induce weight loss, it was plagued by an unacceptable level of serious complications, including hepatic failure, 96 cirrhosis, 97 oxalate kidney stones, bypass enteritis, arthritis, and multiple metabolic deficiencies such as protein malnutrition, metabolic bone disease, hypocalcemia, and vitamin B 12 and vitamin D deficiency. 98 This procedure is no longer performed, and the poor experience with jejunoileal bypass caused a stigma to be associated with bariatric surgery and probably hindered more widespread application of improved operations for obesity. Survivors of this procedure should be evaluated for liver and renal dysfunction and for conversion to a more acceptable anatomic construction whenever possible.
Biliopancreatic Diversion and Duodenal Switch
This procedure uses malabsorption of nutrients because its principal antiobesity mechanism is diversion of biliary and pancreatic secretions to the distal 50 cm of the ileum ( Figure 3B ). 99 A small degree of gastric restriction is added by performing a distal (80%) gastrectomy. The combination of gastroileostomy (rather than gastrojejunostomy), a very long biliopancreatic limb, and a very short common channel results in significant maldigestion and malabsorption of nutrients. This procedure is highly effective in inducing weight loss, particularly in "supermorbid" obese patients (BMI Ͼ 50). However, significant metabolic complications can occur, such as protein calorie malnutrition, metabolic bone disease, and deficiencies in fat-soluble vitamins, iron, calcium, and vitamin B 12 . 99, 100 Most bariatric surgeons are reluctant to perform biliopancreatic diversion as a first-line antiobesity procedure. 35, 100 The duodenal switch procedure (Figure 3C) is a modified form of biliopancreatic diversion that connects the jejunum (rather than ileum) to the proximal duodenum, thus taking advantage of dumping physiology as with Roux-en-Y gastric bypass (GBP). [101] [102] [103] Restrictive Procedures
Gastroplasty
Gastroplasty involves pure restriction of the storage capacity of the stomach to decrease consumption of solid foods. These procedures entail the use of surgical stapling devices and are thus commonly referred to as gastric stapling operations. Initially, gastroplasty consisted of horizontal partitioning of the stomach into a small proximal pouch and a large distal remnant, 104, 105 which communicate through a narrow channel or stoma. Later this was modified by Mason to a vertically oriented gastroplasty with the staple line extending upward from the angle of His, with a mesh-band reinforcement at the stoma on the lesser curvature, and was termed vertical banded gastroplasty (VBG) ( Figure 4A ). 106 VBG was designed to avoid 2 common causes of failure of horizontal partitioning gastroplasty: pouch and stomal dilation. The vertical staple line was primarily to exclude the fundus of the stomach, which was thought to dilate relatively easily, while polypropylene mesh encircling the stoma was used to prevent dilation.
However, a high incidence of stomal stenosis or staple line dehiscence has also been reported with VBG. 107 Although the small pouch and stoma effectively deter ingestion of large boluses of food, many patients learn out of frustration to cheat with high-calorie liquids such as milkshakes. Long-term weight maintenance after VBG has been disappointing, despite the rapid weight loss seen in the first 1-2 years: Nightengale et al. 108 found that only 38% of the patients were able to maintain at least 50% of the excess weight loss at 3 years, and Howard et al. 109 reported a smaller series in which no patient could maintain a 50% excess weight loss by 5 years. Sugerman et al. 110 also found that the mean loss of excess weight was only approximately 38% at 3 years. In these randomized prospective trials, weight loss after VBG was inferior to that after Roux-en-Y GBP, leading many bariatric surgeons to abandon gastroplasty as a primary antiobesity procedure. 35, 111 Gastric Banding Gastric banding, another pure gastric restrictive procedure in which a prosthetic band is encircled around the proximal stomach to compartmentalize it into a small pouch and a large remnant, was initially described by Bo and Modalsli. 112 The absence of a staple line and of the associated risk of staple line dehiscence is a theoretical advantage of this procedure. An adjustable gastric band ( Figure 4B ) was later introduced in which a subcutaneous saline port connected to the adjustable band allows changes in the stoma size. 113 This device may be placed laparoscopically, 114, 115 making it an attractive new device. The results are widely variable but will probably prove comparable to those of VBG. 116 -118 Westling et al. 119 reported a 56% loss of excess weight at 2 years in 90 patients, but with a disappointing 35% conversion to Roux-en-Y gastric bypass. The adjustable gastric band is not yet available in the United States pending the results of a multicenter trial in progress.
Gastric Bypass
Based on the observation that patients with a small proximal gastric remnant after subtotal gastrectomy experienced significant weight loss, GBP was first used to treat obesity by Mason and Ito in 1969. 120,121 The original operation partitioned the stomach into a small proximal cardia and a distal bypassed stomach, with a loop gastrojejunostomy to drain the proximal pouch. Various modifications have been introduced since then, such as Roux-en-Y gastrojejunostomy ( Figure  4C ), 122 in situ compartmentalization of stomach without division, 123 and lengthening of the Roux limb. 124 This procedure is primarily a restrictive operation in that ingestion of a large meal is prevented by a small gastric pouch and a narrow stoma. In addition, the gastrojejunostomy configuration of this operation uses dumping physiology (characterized by lightheadedness, nausea, palpitations, diaphoresis and/or abdominal pain, and diarrhea) as a negative conditioning response when a highcarbohydrate liquid meal is ingested. Thus, after a purely restrictive operation such as VBG, sweets eaters resistant to weight loss because of dietary indiscretions such as high-carbohydrate liquid meals may lose significant weight if their anatomy is reconfigured to Roux-en-Y GBP. 52 Dumping symptoms in response to oral glucose occur specifically in GBP but not in VBG patients, and this phenomenon is closely associated with an elevated serum enteroglucagon level. 125, 126 Both procedures, VBG and GBP, are endorsed by the NIH Consensus Development Panel, but GBP has been shown to be superior to VBG in weight reduction in several randomized, prospective comparisons 109, 110, 127 and has emerged as the gold standard operation. 8 Longterm maintenance of weight loss after GBP has been excellent. Pories et al. 48 reported a series with 58%, 55%, and 49% loss of excess weight at 5, 10, and 14 years from surgery, respectively. More recently, Jones reported a 62% loss of excess weight at 10 years. 111 Modifications that enhance the malabsorptive effects of Roux-en-Y GBP include lengthening the Roux limb (thus shortening the distal common digestive channel). "Long-limb GBP," in which the Roux limb is 150 cm long, compared to the standard 50 -75 cm, 124 "distal GBP," and "very very long Roux limb GBP," in which the distal common digestive channel is shortened to 50 -100 cm, 100 may achieve better weight loss in superobese (BMI Ն 50) patients, although the potential for debilitating malnutrition and vitamin deficiencies exists.
With recent advances in minimally invasive surgical techniques, laparoscopic GBP has become feasible. 128 -131 This technically intensive procedure carries a significant learning curve and requires careful patient selection, including minimal prior upper abdominal surgery, and should initially be reserved for patients at the lower end of the morbid obesity spectrum. In selected patients, laparoscopic GBP can be performed safely and may have advantages of a shorter hospital stay and faster recovery. 131, 132 The perioperative mortality rate of GBP is approximately 1%, and the risk of early postoperative complications is approximately 10%. Major gastrointestinal complications after gastric bypass include anastomotic ulcer, gastrointestinal bleeding, ulcer in bypassed stomach or duodenum, torsion of the Roux limb with volvulus, closed loop obstruction, stomal stenosis, and gallstone formation associated with rapid weight loss. The follow-up series published by Pories et al. 48 is one of the most comprehensive (608 patients) and the longest (14 years), and a summary of the complication rates in their series is shown in Table 4 . Perioperative mortality is largely attributable to sepsis and pulmonary embolus. Wound complications are relatively common in the early postoperative periods. Late complications are dominated by stoma complications (stenosis, ulcer, dilation), staple line disruption, and micronutrient deficiencies. Close affiliation with gastroenterologists who are familiar with the complications of these procedures is a key to the successful long-term treatment of these patients. Because most of the stomach and the duodenum is bypassed in this procedure, potential deficiencies of iron, calcium, thiamine, and vitamin B 12 exist; thus, daily supplements and periodic monitoring of the patient are needed to prevent these deficiencies. Although uncommon, delayed recognition of Wernicke-Korsakoff syndrome from thiamine deficiency may result in serious, irreversible neurologic deficits. Therefore, long-term metabolic surveillance is mandatory in all GBP patients, and patient commitment to prolonged postoperative follow-ups must be a prerequisite to surgery.
Summary
Obesity is a serious chronic medical problem that is increasing at an alarming rate. Although its exact pathogenesis is under intense investigation, it is unlikely that a single gene is responsible for the development of obesity in humans. Significant obesity is associated with numerous comorbid conditions that respond to various therapies directed toward a reduction of excess weight. The goal of treatment of obesity is to improve or resolve comorbid conditions and to improve the quality of life by restoring metabolic and organ function. Available treatment modalities include combinations of diet, exercise, life-style modifications, and adjunctive use of pharmacotherapy and surgery. Nonsurgical modalities provide less invasive initial therapies that should be recommended to all overweight and moderately obese patients. Although safe and effective pharmacotherapeutic agents are currently limited in number and choice, recent advancements in the field of appetite and weight regulation promise more specific and effective drug therapies in the Data from Pories et al. 48 future. Surgical therapy is the most effective modality for treatment of severe obesity. Any individual with obesity should be evaluated carefully for associated comorbidities and risks. Appropriate levels of therapeutic modalities based on the severity of obesity and the associated risks should be offered to patients ( Figure 5) . A multidisciplinary approach, including expert medical, psychologic, and nursing supervision with skilled nutrition, exercise, and behavior counseling, is advocated for patients with medically significant obesity. The end result is to provide appropriate and well-screened patients with a safe and effective means of decreasing morbidity from a wide range of disease states.
